These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 29271010)

  • 21. TOPK: A new predictor of the therapeutic response to neoadjuvant chemotherapy and prognosis in triple-negative breast cancer.
    Wang K; Chai J; Xu J; Wei J; Li P; Liu Y; Ma J; Xu T; Zhao D; Yu K; Fan L; Yan Q; Guo S; Li M; Wang Z
    Pathol Res Pract; 2021 Oct; 226():153603. PubMed ID: 34500374
    [TBL] [Abstract][Full Text] [Related]  

  • 22. NAMPT, GRN, and SERPINE1 signature as predictor of disease progression and survival in gliomas.
    Vachher M; Arora K; Burman A; Kumar B
    J Cell Biochem; 2020 Apr; 121(4):3010-3023. PubMed ID: 31710121
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TOPK/PBK promotes cell migration via modulation of the PI3K/PTEN/AKT pathway and is associated with poor prognosis in lung cancer.
    Shih MC; Chen JY; Wu YC; Jan YH; Yang BM; Lu PJ; Cheng HC; Huang MS; Yang CJ; Hsiao M; Lai JM
    Oncogene; 2012 May; 31(19):2389-400. PubMed ID: 21996732
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of glioma stem cell marker CD133 and O6-methylguanine-DNA methyltransferase is associated with resistance to radiotherapy in gliomas.
    He J; Shan Z; Li L; Liu F; Liu Z; Song M; Zhu H
    Oncol Rep; 2011 Nov; 26(5):1305-13. PubMed ID: 21769436
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of PDZ-binding kinase/T-LAK cell-originated protein kinase (PBK/TOPK) in human urinary bladder transitional cell carcinoma.
    Singh PK; Srivastava AK; Dalela D; Rath SK; Goel MM; Bhatt ML
    Immunobiology; 2014 Jun; 219(6):469-74. PubMed ID: 24629784
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TOPK inhibits autophagy by phosphorylating ULK1 and promotes glioma resistance to TMZ.
    Lu H; Xiao J; Ke C; Ni X; Xiu R; Tian Q; Pan H; Zou L; Wang F; Ma T; Ji X; Yuan P; Liu L; Zhang J; Jia W; Duan Q; Zhu F
    Cell Death Dis; 2019 Aug; 10(8):583. PubMed ID: 31378785
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A restricted signature of serum miRNAs distinguishes glioblastoma from lower grade gliomas.
    Regazzo G; Terrenato I; Spagnuolo M; Carosi M; Cognetti G; Cicchillitti L; Sperati F; Villani V; Carapella C; Piaggio G; Pelosi A; Rizzo MG
    J Exp Clin Cancer Res; 2016 Jul; 35(1):124. PubMed ID: 27476114
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quantitative analysis of matrix metalloproteinase-2 mRNA expression in central and peripheral regions of gliomas.
    Brell M; Ibáñez J; Felpete A; Burguera B; Frontera M; Couce ME
    Brain Tumor Pathol; 2011 Apr; 28(2):137-44. PubMed ID: 21331614
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Downregulation of serum microRNA-205 as a potential diagnostic and prognostic biomarker for human glioma.
    Yue X; Lan F; Hu M; Pan Q; Wang Q; Wang J
    J Neurosurg; 2016 Jan; 124(1):122-8. PubMed ID: 26230475
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
    Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
    Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Downregulation of microRNA-504 is associated with poor prognosis in high-grade glioma.
    Guan Y; Chen L; Bao Y; Pang C; Cui R; Li G; Liu J; Wang Y
    Int J Clin Exp Pathol; 2015; 8(1):727-34. PubMed ID: 25755767
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Overexpression of T-LAK cell-originated protein kinase predicts poor prognosis in patients with stage I lung adenocarcinoma.
    Wei DC; Yeh YC; Hung JJ; Chou TY; Wu YC; Lu PJ; Cheng HC; Hsu YL; Kuo YL; Chen KY; Lai JM
    Cancer Sci; 2012 Apr; 103(4):731-8. PubMed ID: 22192142
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cloning and expression of a novel MAPKK-like protein kinase, lymphokine-activated killer T-cell-originated protein kinase, specifically expressed in the testis and activated lymphoid cells.
    Abe Y; Matsumoto S; Kito K; Ueda N
    J Biol Chem; 2000 Jul; 275(28):21525-31. PubMed ID: 10781613
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Kinesin family member 2C (KIF2C/MCAK) is a novel marker for prognosis in human gliomas.
    Bie L; Zhao G; Wang YP; Zhang B
    Clin Neurol Neurosurg; 2012 May; 114(4):356-60. PubMed ID: 22130050
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High CHI3L1 expression is associated with glioma patient survival.
    Steponaitis G; Skiriutė D; Kazlauskas A; Golubickaitė I; Stakaitis R; Tamašauskas A; Vaitkienė P
    Diagn Pathol; 2016 Apr; 11():42. PubMed ID: 27121858
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tissue microarray analysis for epithelial membrane protein-2 as a novel biomarker for gliomas.
    Chung LK; Pelargos PE; Chan AM; Demos JV; Lagman C; Sheppard JP; Nguyen T; Chang YL; Hojat SA; Prins RM; Liau LM; Nghiemphu L; Lai A; Cloughesy TF; Yong WH; Gordon LK; Wadehra M; Yang I
    Brain Tumor Pathol; 2018 Jan; 35(1):1-9. PubMed ID: 28887715
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ARL3 is downregulated and acts as a prognostic biomarker in glioma.
    Wang Y; Zhao W; Liu X; Guan G; Zhuang M
    J Transl Med; 2019 Jun; 17(1):210. PubMed ID: 31234870
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of EphrinB2 and EphB4 in glioma tissues correlated to the progression of glioma and the prognosis of glioblastoma patients.
    Tu Y; He S; Fu J; Li G; Xu R; Lu H; Deng J
    Clin Transl Oncol; 2012 Mar; 14(3):214-20. PubMed ID: 22374425
    [TBL] [Abstract][Full Text] [Related]  

  • 39. T-lymphokine-activated killer cell-originated protein kinase (TOPK) as a prognostic factor and a potential therapeutic target in glioma.
    Quan C; Xiao J; Duan Q; Yuan P; Xue P; Lu H; Yan M; Guo D; Xu S; Zhang X; Lin X; Wang Y; Dogan S; Zhang J; Zhu F; Ke C; Liu L
    Oncotarget; 2018 Jan; 9(8):7782-7795. PubMed ID: 29487691
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting PBK/TOPK decreases growth and survival of glioma initiating cells in vitro and attenuates tumor growth in vivo.
    Joel M; Mughal AA; Grieg Z; Murrell W; Palmero S; Mikkelsen B; Fjerdingstad HB; Sandberg CJ; Behnan J; Glover JC; Langmoen IA; Stangeland B
    Mol Cancer; 2015 Jun; 14():121. PubMed ID: 26081429
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.